Moderna's trading volume on March 13th was $348 million, ranking 334th among U.S. stocks on that day.

On March 13, 2026, biotechnology company Moderna (MRNA) had a trading value of $348 million, ranking 334th among the U.S. stock market on that day. Its trading value increased by 1.96% compared with the previous day, and its trading volume that day was 6.6025 million shares.

Moderna (MRNA) fell 1.55% on March 13, 2026, to $52.56. Over the past 5 trading days, the stock has risen 0.08%; for the entire month of March, it has fallen 1.89%; since the beginning of the year, it has risen 78.23%; and over the past 52 weeks, it has risen 53.24%.

If the company has been listed for fewer than 52 weeks, the 52-week gain/loss rate is calculated as the gain/loss from the listing date to now (the same applies to cases where it has been listed for fewer than 1 month or fewer than 5 trading days).

Moderna, Inc. was incorporated on July 22, 2016, under the laws of Delaware. The company is a leader in messenger RNA (messenger RNA) medicine. By working for more than ten years at the intersection of science, technology, and health, the company has developed drugs at an unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company’s mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders. With a unique culture and a global team driven by Moderna’s values and ways of thinking, the company strives to responsibly change the future of human health by delivering the greatest possible impact to people through mRNA medicines.